The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting applications to establish the Antiviral Drug Discovery (AViDD) program. AViDD will be comprised of multidisciplinary Centers focused on:
- The discovery and development of new antiviral drug candidates and lead series with the aim of generating a more robust pipeline of novel antivirals targeting the immediate threat of SARS-CoV-2
- Providing antiviral drug candidates that might quickly pivot to address future viral outbreaks or pandemics
How to Apply
Funding Opportunity Announcement (FOA), AI-21-050 is open until October 22, 2021. Potential applicants are encouraged to review the FOA for further details.
Antiviral Program for Pandemics
AViDD is part of NIAID's Antiviral Program for Pandemics (APP) which aims to develop antivirals to combat SARS-CoV-2, build sustainable platforms for drug discovery, and develop a pipeline of antivirals against viruses with pandemic potential.